Artelo Biosciences

ARTL · NASDAQ

$2.62−$0.04 (−1.50%)TodayMarket closed · Oct 20, 5:43 PM ET

Prev close $2.66

ARTL analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $30.60 (+1067.9% upside)

Low: $30.30
Now: $2.62
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

ARTL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Hit rate
Maxim Group	Nov 19, 2025	Downgrade	Buy → Hold	27%

The case for and against

Updated Feb 9, 2026

Bull case

Artelo Biosciences Inc. exhibits a strong positive outlook due to early clinical data demonstrating significant improvements in biomarkers related to muscle mass and weight maintenance, suggesting potential clinical benefits. The company's focus on developing patent-protected cannabinoid drug combination treatments for rare diseases is supported by compelling scientific evidence and a substantial market opportunity. Additionally, the potential for future value inflection is closely tied to upcoming clinical readouts, indicating a strategic advancement in their therapeutic offerings.

Bear case

Artelo Biosciences Inc. has experienced a recent $3 million capital raise, which introduces uncertainty and potential dilution of its stock. This capital raise, coupled with a confusing strategic direction involving a crypto-related initiative, contributes to a negative outlook due to likely downward pressure on valuation, especially for an early-stage biopharmaceutical firm that may need further fundraising to achieve key clinical milestones. Additionally, the combination of poor communication from the company and a lack of clear strategy raises concerns about investor confidence and future financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.